Oncology and Hematology Research

At Uniwersytecki Szpital Dzieciecy W Lublinie, clinical trials in neoplasms and hemic and lymphatic diseases focus on childhood cancers such as acute lymphoblastic leukemia, relapsed ALL, lymphoblastic lymphoma, and myeloid leukemia in children with Down syndrome. The studies are designed to improve treatment effectiveness, reduce relapse risk, and support safer cancer care for young patients.

  • Testing new treatment combinations for acute lymphoblastic leukemia and relapsed ALL
  • Evaluating strategies to improve remission, survival, and minimal residual disease response
  • Supporting safer and more effective care in pediatric oncology

This area also includes work on hematopoietic stem cell transplantation in pediatric leukemia, reflecting a strong focus on advanced therapies for children with high-risk disease.

Transplantation and Immune System Studies

The site conducts research on HSCT, graft-versus-host disease, and immune-related complications in children with leukemia. These trials aim to refine transplant care, lower treatment-related toxicity, and preserve the beneficial anti-leukemia effect of transplantation.

  • Improving stem cell transplantation approaches in pediatric ALL
  • Studying ways to reduce transplant-related toxicity while maintaining disease control
  • Evaluating treatments for acute graft-versus-host disease and post-transplant relapse prevention

The research includes cooperative efforts on transplant conditioning, donor-related strategies, and maintenance therapy after HSCT.

Kidney and Metabolic Diseases

Trials in nutritional and metabolic diseases and pathological conditions address pediatric kidney disorders and early diabetes-related disease. Key conditions include nephrotic syndrome, IgA nephropathy, chronic kidney disease, and presymptomatic type 1 diabetes. The goal is to improve disease control and evaluate new treatment options in children.

  • Assessing therapies for proteinuria and kidney inflammation
  • Studying treatments for chronic kidney disease in children at risk of progression
  • Exploring early immune-based intervention in stage 1 type 1 diabetes

These studies reflect a broad pediatric nephrology and metabolic research profile at the Lublin children’s hospital.

Rheumatology and Autoimmune Care

Research in immune system diseases and skin and connective tissue diseases includes pediatric juvenile idiopathic arthritis, juvenile psoriatic arthritis, and lichen sclerosus. The trials are focused on testing new therapies, understanding treatment response, and improving symptom control in chronic inflammatory conditions.

  • Evaluating biologic and targeted treatments for juvenile arthritis
  • Comparing therapies for pediatric vulval lichen sclerosus
  • Studying safety, effectiveness, and patient response in autoimmune disease care

This work helps expand treatment options for children with long-term inflammatory disorders treated at the hospital.

Bleeding and Blood Disorder Research

The site also investigates hemophilia, chronic immune thrombocytopenic purpura, and related bleeding disorders. These studies aim to reduce bleeding episodes, improve prophylactic care, and better manage platelet and clotting problems in children.

  • Testing new approaches to prevent bleeding in hemophilia A and B
  • Evaluating treatment options for chronic ITP
  • Improving long-term management of pediatric bleeding disorders

The research contributes to safer and more effective care for children with inherited or immune-mediated blood disorders.

Supportive Care in Pediatric Cancer

A further part of the trial portfolio addresses chemotherapy-induced nausea and vomiting in children receiving cancer treatment. These studies focus on improving comfort, tolerability, and overall quality of care during intensive therapy.

  • Comparing approaches to prevent nausea and vomiting during cancer therapy
  • Assessing supportive treatments that may improve the treatment experience for young patients
  • Strengthening pediatric oncology supportive care

This research complements the hospital’s broader oncology program by addressing side effects that can affect treatment adherence and wellbeing.